Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis

• Published in: Voprosy onkologij Vol. 52; no. 5; p. 531
• Main Authors: Kharchenko, V P, Datsenko, P V, Panyshin, G A, Sotnikov, V M, Mel'nik, Iu D
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2006
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bleomycin - administration & dosage; Carboplatin - administration & dosage; Dacarbazine - administration & dosage; Disease-Free Survival; Doxorubicin - administration & dosage; Drug Administration Schedule; Etoposide - administration & dosage; Female; Follow-Up Studies; Hodgkin Disease - drug therapy; Hodgkin Disease - pathology; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Treatment Outcome; Vinblastine - administration & dosage
• ISSN: 0507-3758

Data are presented on our 5-year experience with combination chemotherapy of stage II-IV Hodgkin's disease (110), the unfavorable prognosis group, using a novel regimen of chemotherapy--CEA/ABVD (belustin, etoposide, doxorubicin, bleomycin, vinblastine, dacarbazine). Complete remission after 4 courses of CEA/ABVD chemotherapy was reported in 31.8%, unconfirmed complete remission--45.5%, objective effect--100% and an 80% regression of tumor mass--93.2%. No chemo-resistant forms were identified. Five-year actuarial relapse-free survival was 96.4%; overall 5-year survival--97.7%. Death from complications recorded during medication period occurred in 2.3% (1 out of 44), recurrence--2.3% (1 out of 44). Recurrence-free survival rose by 25% (p < 0.05) while overall survival--by 20% (p = 0.04 in year 3), as compared with COOP(MOPP)/ABVD (179 patients with poor prognosis). Our regimen opens up new vistas in managing Hodgkin's disease.